Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022. In the quarter to June 2026, EPS grew 26.5% and free cash flow fell 50.1%, each against the same quarter a year earlier.
Follow SYRE
Spyre Therapeutics, Inc. (SYRE) Piotroski F-score
Spyre Therapeutics, Inc.'s Piotroski F-score for fiscal 2023 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2018.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2023 | 3 | 1.00 |
| FY2018 | 2 | 0.00 |
| FY2017 | 2 | — |
How fiscal 2023’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (164.06%) | (92.58%) | Fail | 0 |
| Positive operating cash flow | (99.91m) | (80.14m) | Fail | 0 |
| Rising return on assets | (164.06%) | (92.58%) | Fail | 0 |
| Cash flow above net income | 238.88m | 3.67m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 10.68 | 4.25 | Pass | 1 |
| No new shares issued | 6,897,100 | 3,371,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.00 | 0.03 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 5 |
| AXSM Axsome Therapeutics, Inc. compare | 5 |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 5 |
| IONS Ionis Pharmaceuticals, Inc. compare | 4 |
| IOVA Iovance Biotherapeutics, Inc. compare | 4 |
| PTGX Protagonist Therapeutics, Inc. compare | 4 |
| SYRE Spyre Therapeutics, Inc. | 3 |
| ABVX Abivax SA Sponsored ADR compare | — |
| PRAX Praxis Precision Medicines, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover